Braidwell LP Invests $532,000 in Cyclerion Therapeutics, Inc. $CYCN

Braidwell LP acquired a new stake in shares of Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) during the second quarter, HoldingsChannel reports. The firm acquired 156,890 shares of the company’s stock, valued at approximately $532,000.

Other large investors have also modified their holdings of the company. Two Sigma Investments LP bought a new position in Cyclerion Therapeutics in the third quarter worth $31,000. BlackRock Inc. acquired a new stake in Cyclerion Therapeutics during the second quarter worth $57,000. Finally, ADAR1 Capital Management LLC bought a new stake in Cyclerion Therapeutics in the 2nd quarter valued at $1,013,000. 75.62% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Cyclerion Therapeutics in a research note on Friday, July 24th. One analyst has rated the stock with a Sell rating, According to MarketBeat, the company presently has an average rating of “Sell”.

Cyclerion Therapeutics Price Performance

Shares of NASDAQ:CYCN opened at $4.52 on Thursday. The business’s fifty day moving average price is $3.70 and its two-hundred day moving average price is $3.00. Cyclerion Therapeutics, Inc. has a fifty-two week low of $1.03 and a fifty-two week high of $8.48. The stock has a market capitalization of $21.15 million, a price-to-earnings ratio of -2.72 and a beta of 1.75.

Cyclerion Therapeutics’s stock is scheduled to reverse split on Wednesday, September 9th. The 1-7 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the closing bell on Tuesday, September 8th.

Cyclerion Therapeutics (NASDAQ:CYCN) last issued its quarterly earnings data on Tuesday, August 4th. The company reported ($0.41) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($7.10) by $6.69. Cyclerion Therapeutics had a negative return on equity of 87.96% and a negative net margin of 170.11%. Research analysts expect that Cyclerion Therapeutics, Inc. will post -1.2 EPS for the current fiscal year.

Cyclerion Therapeutics Profile

Cyclerion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of inhibitors and stimulators of soluble guanylate cyclase (sGC), an intracellular enzyme that plays a critical role in the regulation of vascular tone, cellular proliferation and inflammation. By targeting the nitric oxide (NO)–sGC–cyclic guanosine monophosphate (cGMP) signaling pathway, Cyclerion aims to address a range of cardiometabolic, cardiovascular, pulmonary and neurological disorders with significant unmet medical need.

The company’s lead program, praliciguat, is an oral sGC stimulator investigated for indications such as diabetic nephropathy, metabolic syndrome and heart failure with preserved ejection fraction.